Todd E. Golde on Early Events in AD Mice as Targets for Therapy

COMMENT I think we in this field have to be careful with overinterpreting phenomena in our APP mouse models. Transgenic mouse models expressing AD-associated mutant forms of the amyloid-β precursor protein (APP), or both mutant APP and mutant presenilin-1 (PS1), ...

Todd E. Golde on SfN: R-Flurbiprofen Phase 2 Trial Results

COMMENT It is important to clarify the statement "Flurbiprofen is the only approved NSAID still in the running for an AD therapy, though the one discussed here is a version trademarked by Myriad Pharmaceuticals. " The drug under investigation is R ...

Todd E. Golde on Naproxen/Rofecoxib Trial Results Published

COMMENT The study by Aisen et al. shows no benefit to rofecoxib or naproxen in patients with mild to moderate AD. Nevertheless, this negative study is an important contribution to the collective effort to evaluate therapeutic strategies to treat or prevent AD. ...

Current Filters

  • TYPE: Comment x
  • Commentator: Golde, Todd E. x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From